Your browser is no longer supported. Please, upgrade your browser.
ACAD ACADIA Pharmaceuticals Inc. daily Stock Chart
ACAD [NASD]
ACADIA Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.58 Insider Own0.10% Shs Outstand155.37M Perf Week-1.71%
Market Cap8.03B Forward P/E- EPS next Y-0.59 Insider Trans188.40% Shs Float155.70M Perf Month0.47%
Income-238.00M PEG- EPS next Q-0.44 Inst Own99.10% Short Float7.38% Perf Quarter25.82%
Sales366.20M P/S21.92 EPS this Y17.50% Inst Trans2.74% Short Ratio8.34 Perf Half Y7.66%
Book/sh4.11 P/B12.45 EPS next Y78.20% ROA-34.50% Target Price57.82 Perf Year97.11%
Cash/sh4.15 P/C12.32 EPS next 5Y25.00% ROE-39.40% 52W Range21.56 - 53.70 Perf YTD19.61%
Dividend- P/FCF- EPS past 5Y-10.90% ROI-35.40% 52W High-4.71% Beta1.81
Dividend %- Quick Ratio7.20 Sales past 5Y390.00% Gross Margin94.50% 52W Low137.34% ATR2.39
Employees550 Current Ratio7.30 Sales Q/Q43.00% Oper. Margin-67.80% RSI (14)57.23 Volatility3.59% 5.04%
OptionableYes Debt/Eq0.00 EPS Q/Q4.40% Profit Margin-65.00% Rel Volume0.83 Prev Close51.17
ShortableYes LT Debt/Eq0.00 EarningsMay 07 AMC Payout- Avg Volume1.38M Price51.17
Recom1.80 SMA203.27% SMA5013.61% SMA20022.52% Volume0 Change0.00%
Apr-16-20Initiated Jefferies Buy $60
Mar-31-20Upgrade Goldman Neutral → Buy $45 → $72
Mar-06-20Initiated Citigroup Buy $69
Dec-16-19Initiated Guggenheim Buy $60
Oct-24-19Initiated Oppenheimer Perform $44
Oct-01-19Initiated RBC Capital Mkts Outperform $60
Sep-13-19Upgrade SVB Leerink Mkt Perform → Outperform
Sep-10-19Upgrade Canaccord Genuity Hold → Buy $29 → $50
Jul-23-19Reiterated Needham Buy $40 → $34
Dec-10-18Initiated Canaccord Genuity Hold $23
Sep-21-18Upgrade Piper Jaffray Neutral → Overweight
Aug-09-18Reiterated Stifel Hold $17 → $14
Aug-07-18Initiated Stifel Hold $17
Aug-06-18Downgrade Piper Jaffray Overweight → Neutral
Oct-06-17Resumed Goldman Neutral
Nov-11-16Initiated Goldman Neutral
Nov-08-16Upgrade BofA/Merrill Neutral → Buy
Oct-19-16Resumed ROTH Capital Neutral
Oct-04-16Initiated Leerink Partners Mkt Perform $34
Jun-22-16Downgrade BofA/Merrill Buy → Neutral
May-26-20 09:00AM  ACADIA Pharmaceuticals to Combine CLARITY-2 and CLARITY-3 Phase 3 Studies Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder Business Wire
May-21-20 11:28PM  Edited Transcript of ACAD earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents
09:00AM  ACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020 American Society of Clinical Psychopharmacology Virtual Annual Meeting Business Wire
May-09-20 08:02AM  Analysts Have Made A Financial Statement On ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) First-Quarter Report Simply Wall St.
May-08-20 10:31PM  Acadia Pharmaceuticals (ACAD) Q1 2020 Earnings Call Transcript Motley Fool
10:55AM  ACADIA's (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates Zacks
May-07-20 06:10PM  Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:06PM  ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results Business Wire
04:05PM  ACADIA Pharmaceuticals and Vanderbilt University Announce Exclusive License Agreement and Research Collaboration Business Wire
May-05-20 04:05PM  ACADIA Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences Business Wire
Apr-30-20 12:34PM  Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Apr-15-20 04:05PM  ACADIA Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 7, 2020 Business Wire
Apr-13-20 09:43AM  We're Not Worried About ACADIA Pharmaceuticals's (NASDAQ:ACAD) Cash Burn Simply Wall St.
Mar-27-20 11:31AM  Why Is Acadia (ACAD) Up 1.1% Since Last Earnings Report? Zacks
Mar-24-20 04:23PM  Biotech stocks have held up better than the broader market and these five are potential winners MarketWatch +8.74%
Mar-22-20 05:04PM  Largest Insider Trades of the Week GuruFocus.com
Mar-20-20 02:11PM  Hedge Funds Have Never Been This Bullish On ACADIA Pharmaceuticals Inc. (ACAD) Insider Monkey
Mar-17-20 12:06AM  Edited Transcript of ACAD earnings conference call or presentation 26-Feb-20 10:00pm GMT Thomson Reuters StreetEvents +8.63%
Mar-03-20 05:50PM  ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome Business Wire
Feb-28-20 08:35PM  Dont Expect Virgin Galactic Shares to Keep Rocketing Upward Barrons.com +9.31%
01:54PM  ACADIA Pharmaceuticals Inc. Just Released Its Yearly Results And Analysts Are Updating Their Estimates Simply Wall St.
Feb-27-20 11:13AM  ACADIA (ACAD) Q4 Earnings Surpass, Nuplazid Drives Sales Zacks
Feb-26-20 05:35PM  Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:05PM  ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire
Feb-24-20 09:00AM  ACADIA Pharmaceuticals to Present at the Cowen and Company 40th Annual Health Care Conference on March 2, 2020 Business Wire -6.38%
Feb-19-20 12:31PM  Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Feb-12-20 09:00AM  ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020 Business Wire
Feb-05-20 06:13AM  Analysts Expect Breakeven For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Simply Wall St.
Jan-29-20 05:00AM  ACADIA- From Depression to Schizophrenia MoneyShow
Jan-17-20 08:45AM  ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why Zacks
Jan-10-20 11:54AM  How Did ACADIA Pharmaceuticals Inc. (ACAD) Perform In Comparison to Hedge Fund Favorites in 2019? Insider Monkey
Jan-07-20 09:00AM  ACADIA Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020 Business Wire
Dec-23-19 02:47PM  Investors flock to neuro drug makers after FDA approves new schizophrenia drug MarketWatch
11:30AM  Has ACADIA Pharmaceuticals (ACAD) Outpaced Other Medical Stocks This Year? Zacks
Dec-22-19 07:12AM  Can You Imagine How Chuffed ACADIA Pharmaceuticals's (NASDAQ:ACAD) Shareholders Feel About Its 215% Share Price Gain? Simply Wall St.
Dec-19-19 10:18AM  Biotech Stock Outlook: M&A Activity Retains Growth Streak Zacks
Dec-18-19 04:05PM  ACADIA Pharmaceuticals Appoints Stephanie Fagan as Senior Vice President, Corporate Affairs and Chief Communications Officer Business Wire -5.81%
Dec-17-19 09:11AM  5 Biotech Stocks That Have More Than Doubled This Year Zacks
Dec-12-19 11:56AM  The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech Zacks
Dec-11-19 09:04AM  5 Biotech Stocks Up More Than 100% This Year So Far Zacks
Dec-06-19 07:39AM  The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend Benzinga
05:00AM  A 60% Tumble for Sage Therapeutics, and Two More Numbers to Know Barrons.com
Dec-05-19 11:01PM  Hedge Funds Snapped Up ACADIA Pharmaceuticals Inc. (ACAD) Before The Q4 Rally Insider Monkey +14.00%
04:08PM  Why This Highflying Biotech Stock Zoomed Near A Profit-Taking Zone Investor's Business Daily
10:08AM  Biotech Stocks Are Making Wild Moves Amid a Deluge of Trial Data Barrons.com
07:14AM  The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission Benzinga
Dec-04-19 08:45PM  Acadia Pharma's psychosis drug proven better than placebo in dementia patients Reuters
08:45PM  ACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on Alzheimers Disease (CTAD) Meeting Business Wire
Dec-02-19 02:57PM  7 Exciting Biotech Stocks to Buy Now InvestorPlace
Dec-01-19 09:30AM  The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More Benzinga
07:27AM  3 Monster Growth Stocks That Are Still in the Buy Zone TipRanks
Nov-27-19 10:00AM  What Makes Acadia Pharmaceuticals (ACAD) a Strong Momentum Stock: Buy Now? Zacks
Nov-25-19 04:03PM  ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia Business Wire
08:58AM  Top Ranked Momentum Stocks to Buy for November 25th Zacks
Nov-21-19 09:56AM  The Medicines Company Soars Amid Acquisition Whispers Investopedia
Nov-18-19 10:17AM  Medtronic (MDT) to Report Q2 Earnings: What's in Store? Zacks
Nov-12-19 08:18AM  The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene Zacks
Nov-11-19 04:48PM  IBD Stock Of The Day Breaks Out As It Stares Down A Massive Opportunity Investor's Business Daily +6.17%
09:28AM  4 Biotech Stocks That Could Keep Beating Wall Street Zacks
09:00AM  ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimers Disease (CTAD) Meeting on December 4, 2019 Business Wire
Nov-07-19 05:13AM  Have Insiders Been Selling ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares? Simply Wall St.
Nov-06-19 10:00AM  What Makes Acadia Pharmaceuticals (ACAD) a Strong Momentum Stock: Buy Now? Zacks
09:00AM  Acadia (ACAD) Upgraded to Buy: Here's Why Zacks
Nov-04-19 05:40PM  Edited Transcript of ACAD earnings conference call or presentation 30-Oct-19 8:30pm GMT Thomson Reuters StreetEvents
09:00AM  ACADIA Pharmaceuticals Appoints Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer Business Wire
Oct-30-19 07:25PM  Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:15PM  ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder Business Wire
04:05PM  ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results Business Wire
Oct-29-19 08:46AM  Cigna (CI) to Report Q3 Earnings: What's in the Offing? Zacks
Oct-28-19 11:22AM  Teladoc (TDOC) to Report Q3 Earnings: What's in the Cards? Zacks
Oct-25-19 12:12PM  Will Nuplazid Aid Growth for ACADIA (ACAD) in Q3 Earnings? Zacks
Oct-24-19 04:58PM  Hedge Funds Are Betting On ACADIA Pharmaceuticals Inc. (ACAD) Again Insider Monkey
Oct-23-19 10:33AM  Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Oct-16-19 09:00AM  ACADIA Pharmaceuticals to Announce Third Quarter 2019 Financial Results on October 30, 2019 Business Wire
Oct-09-19 11:18AM  Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates Zacks
Oct-08-19 06:00AM  Acadia Sees Strong Results in Dementia Treatment MoneyShow
Oct-07-19 09:00AM  ACADIA Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study with Pimavanserin in Adjunctive Major Depressive Disorder at 2019 Psych Congress Business Wire
Oct-03-19 04:55PM  ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in Dementia-Related Psychosis at the Clinical Trials on Alzheimers Disease (CTAD) 2019 Meeting Business Wire
Oct-02-19 06:37AM  We Think ACADIA Pharmaceuticals (NASDAQ:ACAD) Can Easily Afford To Drive Business Growth Simply Wall St.
Sep-26-19 09:14AM  Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar? Zacks
Sep-25-19 04:05PM  ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019 Business Wire
Sep-24-19 04:05PM  ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder Business Wire -7.07%
Sep-23-19 09:00AM  ACADIA Pharmaceuticals Presents New Data on PD Patients Treated with Pimavanserin for Depression at the 2019 International Congress of Parkinsons Disease and Movement Disorders Business Wire
Sep-20-19 04:05PM  ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
01:10PM  Gilead, AbbVie Are Innovative, but May Be Underappreciated GuruFocus.com
Sep-19-19 09:00AM  ACADIA Pharmaceuticals to Present New Clinical Data and Outcomes Research at Upcoming Scientific Meetings Business Wire
Sep-17-19 11:00PM  ACADIA Pharmaceuticals Prices Public Offering of Common Stock Business Wire
04:02PM  ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
03:25PM  5 Top Stock Trades for Wednesday: BA, ACB, PINS InvestorPlace
Sep-11-19 10:23AM  3 Hot Biotechs with High Upside Potential TipRanks
Sep-10-19 01:20PM  'Pleasantly Surprised' Acadia Analysts See Blockbuster Potential For Pimavanserin In Dementia Psychosis Benzinga +6.10%
11:41AM  ACADIA Surges on Early Success of Nuplazid Dementia Study Zacks
10:59AM  Will ACADIA Continue to Surge Higher? Zacks
08:39AM  Is Acadia Pharmaceuticals a Good Biotech Stock to Buy Now? Motley Fool
07:36AM  The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris Benzinga
Sep-09-19 05:38PM  Why Acadia Pharmaceuticals Stock Skyrocketed Today Motley Fool +63.24%
04:55PM  ACADIA Pharmaceuticals Help Lift Biotech ETFs ETF Trends
04:26PM  Why This Biotech Stock Just Rocketed 63% After Hitting A 4-Year High Investor's Business Daily
04:13PM  What Happened in the Stock Market Today Motley Fool
02:33PM  Acadia Stops Nuplazid Study Early After Drug Shows 'Statistically Superior Efficacy' In Dementia-Related Psychosis Benzinga
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DAVIS STEPHENCEOMay 14Option Exercise19.6588,5421,739,850100,351May 15 07:11 PM
DAVIS STEPHENCEOMay 14Sale45.6288,5424,039,10511,809May 15 07:11 PM
DAVIS STEPHENCEOMay 13Option Exercise19.65111,4582,190,150123,267May 15 07:11 PM
DAVIS STEPHENCEOMay 13Sale46.35111,4585,165,58711,809May 15 07:11 PM
Daly James MDirectorMay 11Option Exercise26.3926,250692,70026,250May 13 06:00 PM
Daly James MDirectorMay 11Sale51.1326,2501,342,1780May 13 06:00 PM
DAVIS STEPHENCEOApr 30Sale49.216,770333,15211,809May 01 06:00 PM
YANG MICHAEL J.EVP and CCOApr 30Sale49.211,50173,8645,204May 01 06:00 PM
KIM AUSTIN D.EVP & General CounselApr 30Sale49.221,07252,7642,441May 01 06:00 PM
Stankovic Srdjan R.PresidentApr 30Sale49.214,308211,99711,334May 01 06:00 PM
Ridloff ElenaEVP and CFOApr 30Sale49.221,05051,6812,195May 01 06:00 PM
Ridloff ElenaEVP and CFOApr 29Option Exercise25.1210,000251,20010,000May 01 06:00 PM
Ridloff ElenaEVP and CFOApr 29Sale50.7410,000507,3530May 01 06:00 PM
Stankovic Srdjan R.PresidentApr 23Option Exercise20.6718,949391,70424,976Apr 24 06:00 PM
Stankovic Srdjan R.PresidentApr 23Sale50.0718,949948,7296,027Apr 24 06:00 PM
Stankovic Srdjan R.PresidentApr 22Option Exercise19.7754,0191,067,95660,046Apr 22 06:30 PM
Stankovic Srdjan R.PresidentApr 22Sale50.0254,0192,701,9066,027Apr 22 06:30 PM
Stankovic Srdjan R.PresidentApr 20Option Exercise19.65100,0001,965,000106,027Apr 22 06:30 PM
Stankovic Srdjan R.PresidentApr 20Sale50.15100,0005,015,4506,027Apr 22 06:30 PM
BAKER BROS. ADVISORS LPDirectorMar 18Buy33.52135,8974,555,10138,433,977Mar 18 06:47 PM
BAKER BROS. ADVISORS LPDirectorMar 17Buy32.84219,8007,218,90738,309,339Mar 18 06:47 PM
BAKER BROS. ADVISORS LPDirectorMar 16Buy31.51694,30321,878,01738,107,749Mar 18 06:47 PM
Brege LauraDirectorJan 07Option Exercise1.7510,00017,50010,000Jan 08 06:01 PM
Brege LauraDirectorJan 07Sale42.1910,000421,9000Jan 08 06:01 PM
YANG MICHAEL J.EVP and CCODec 12Option Exercise31.09105,4793,279,377107,978Dec 13 05:35 PM
YANG MICHAEL J.EVP and CCODec 12Sale44.46105,4794,689,2632,499Dec 13 05:35 PM
KIM AUSTIN D.EVP & General CounselDec 11Option Exercise17.5817,500307,65018,009Dec 13 05:34 PM
KIM AUSTIN D.EVP & General CounselDec 11Sale45.0617,500788,576509Dec 13 05:34 PM
Ridloff ElenaEVP and CFODec 09Option Exercise15.8136,000569,16036,000Dec 11 06:29 PM
YANG MICHAEL J.EVP and CCODec 09Option Exercise35.8614,521520,72316,144Dec 11 06:30 PM
YANG MICHAEL J.EVP and CCODec 09Sale50.4614,521732,7921,623Dec 11 06:30 PM
Ridloff ElenaEVP and CFODec 09Sale49.6636,0001,787,8530Dec 11 06:29 PM
DAVIS STEPHENCEODec 05Option Exercise19.65150,0002,947,500152,954Dec 06 06:25 PM
DAVIS STEPHENCEODec 05Sale52.34150,0007,851,3002,954Dec 06 06:25 PM
Stankovic Srdjan R.PresidentNov 19Sale46.412,160100,2466,027Nov 21 05:37 PM
Miller Eric AlejandroController & PAOOct 15Sale39.651475,829270Oct 17 06:26 PM
YANG MICHAEL J.EVP and CCOOct 15Sale39.6587734,7731,623Oct 17 06:25 PM
Stankovic Srdjan R.PresidentOct 15Sale39.651,03140,8791,937Oct 17 06:24 PM
DAVIS STEPHENCEOOct 15Sale39.652,983118,2762,954Oct 17 06:23 PM
DAVIS STEPHENCEOOct 10Option Exercise19.65120,2082,362,087120,208Oct 11 05:39 PM
DAVIS STEPHENCEOOct 10Sale40.19120,2084,831,0390Oct 11 05:39 PM
DAVIS STEPHENCEOOct 09Option Exercise19.6529,792585,41329,792Oct 11 05:39 PM
DAVIS STEPHENCEOOct 09Sale40.0029,7921,191,7100Oct 11 05:39 PM
BAKER BROS. ADVISORS LPDirectorSep 20Buy40.001,562,50062,500,00037,470,965Sep 20 04:28 PM
Miller Eric AlejandroController & PAOSep 11Sale41.184,645191,2810Sep 11 07:19 PM
Daly James MDirectorSep 09Option Exercise17.5230,000525,60030,000Sep 11 07:18 PM
Miller Eric AlejandroController & PAOSep 09Option Exercise28.7128,467817,21833,112Sep 11 07:19 PM
Miller Eric AlejandroController & PAOSep 09Sale39.4928,4671,124,1624,645Sep 11 07:19 PM
Daly James MDirectorSep 09Sale37.8030,0001,133,8600Sep 11 07:18 PM